Raf kinase inhibitor protein (RKIP) is a modulator of cell signaling that functions as an endogenous inhibitor of multiple kinases. We demonstrate here a positive role for RKIP in the regulation of cell locomotion. We discovered that RKIP is the relevant cellular target of locostatin, a cell migration inhibitor. Locostatin abrogates RKIP's ability to bind and inhibit Raf-1 kinase, and it acts by disrupting a protein-protein interaction, an uncommon mode of action for a small molecule. Small interfering RNA-mediated silencing of RKIP expression also reduces cell migration rate. Overexpression of RKIP converts epithelial cells to a highly migratory fibroblast-like phenotype, with dramatic reduction in the sensitivity of cells to locostatin. RKIP is therefore the compound's valid target and a key regulator of cell motility.
Introduction
We previously described the biological activity of the oxazolidinone derivative UIC-1005 [1] . We now rename this compound locostatin, after its ability to inhibit cell locomotion in multiple systems, and have identified its cellular protein targets, which we present here. Our interest in locostatin's mode of action arose from discovery of its inhibitory activity in a high-throughput assay for compounds that affect cell migration during wound closure in Madin-Darby canine kidney (MDCK) epithelial cell monolayers. This screen was performed as part of our effort to apply a chemical approach to understanding the pathways and machinery of cell motility, processes for which small-molecule inhibitors are presently limited, with the goal of discovering new chemical probes and possibly new proteins involved in cell migration (for a review, see [2] ). Moreover, small molecules that modulate cell migration could be of therapeutic value: for instance, antimigratory compounds could be exploited as anticancer agents, since both tumor angiogenesis and metastasis depend on cell migration, while promigratory compounds could be used to improve wound healing or may have applications in tissue engineering. In this report, we show that the biologically relevant target of locostatin is Raf kinase inhibitor protein (RKIP), a nonenzymatic regulatory pro-*Correspondence: fenteany@uic.edu tein whose ability to interact with Raf kinase is disrupted by locostatin.
RKIP is a widely expressed modulator of the Raf kinase cascade and other signaling pathways (for reviews, see [3] [4] [5] ). RKIP associates with and inhibits the kinase activity of Raf-1 kinase [6, 7] . Phosphorylation of RKIP by protein kinase C (PKC) switches RKIP from Raf-1 to G protein receptor coupled kinase 2 (GRK2) [8, 9] . RKIP has recently been found to interact with and antagonize the kinase activity of B-Raf as well [10] , although Raf-1 activation in vivo may be more under the control of RKIP than B-Raf activation [11] . In addition, RKIP can inhibit activation of the transcriptional regulator nuclear factor κB (NFκB) by interacting with and inhibiting the activities of kinases involved in NFκB activation [12] . RKIP was originally isolated on the basis of its ability to bind phosphatidylethanolamine [13] . It is therefore also known as phosphatidylethanolamine binding protein (PEBP), and it can interact with other ligands as well, although the functional significance of these interactions is unclear (for reviews, see [3] [4] [5] ). RKIP is also the precursor of hippocampal cholinergic neurostimulating peptide (for a review, see [14] ).
Roles for RKIP in diverse biological processes, including nervous and cardiac functions, membrane biogenesis, and spermatogenesis, have been suggested (for reviews, see [3] [4] [5] ). Furthermore, RKIP may play a negative role in prostate cancer metastasis [15] . In contrast, using a chemical approach to the discovery of biological function, we have discovered that RKIP is also involved in the positive regulation of epithelial cell migration.
Results and Discussion

Identification of Locostatin Binding Proteins
Locostatin (compound 1 in Figure 1A ) strongly inhibits membrane protrusion and cell sheet migration, without affecting gross actin cytoskeletal structure in cells or salt-induced polymerization of pyrene-actin in vitro ( [1] and data not shown). The compound also inhibits scatter of MDCK cells, induced by hepatocyte growth factor/scatter factor (HGF/SF), and migration of B16-BL6 murine melanoma cells, a highly invasive and metastatic cancer cell line, with comparable IC 50 values (Table S1; see the Supplemental Data available with this article online). In contrast, locostatin has comparatively little subtoxic antimigratory effect on the less aggressive A549 human lung adenocarcinoma and MCF7 human breast adenocarcinoma cells (Table S1 ).
Since structure-activity relationships strongly suggested that the mechanism of action of locostatin involves covalent modification of a target molecule(s) (Table 1 and [1]), we decided to prepare a radioactively labeled version of the compound, [ 3 H]locostatin (1* in Figure 1B) Figure 2. (B) Scheme for synthesis of 1* by N-acylation of the starting oxazolidinone 4 with the mixed anhydride 3 to form 5, reduction of the acetylene group of 5 with tritium gas to generate 6*, and isomerization of the resulting crotonyl group to yield 1*. 3 H]locostatin, we purified all four of these locostatin binding proteins from MDCK cell lysates. We determined the identity of these proteins by microcapillary HPLC-linear ion trap tandem mass spectrometry (MS) as: (1) the signaling modulator RKIP (w21 kDa); (2) the mechanistically novel glutathione S-transferase (GST) omega 1-1, or GSTO1-1 (w30 kDa); (3) aldehyde dehydrogenase 1A1, or ALDH1A1 (w55 kDa); and (4) prolyl oligopeptidase (POP), also known as prolyl endopeptidase (w80 kDa). In addition to isolation and identification of the proteins from MDCK cell lysates, we purified ALDH1A1 from A549 cells and bovine liver. We also expressed the cloned recombinant genes for RKIP, GSTO1-1, and POP. (Figure 2A ) and bacterially expressed recombinant rat RKIP ( Figure 2B) . We calculated the second-order rate constant for association of locostatin with RKIP as 13.09 M −1 s −1 (Table S2) Locostatin hinders the ability of RKIP to inhibit Raf-1 kinase in vitro, thereby restoring the kinase activity of Raf-1 ( Figure 3A ) and making it, to our knowledge, the first inhibitor of RKIP discovered. Locostatin has no direct effect on the activity of Raf-1 kinase alone in control experiments; however, it is weakly inhibitory of substrate phosphorylation at elevated concentrations of R1 mM, most likely as a result of nonspecific alkylation Treatment with locostatin appears to cause a morphological change of the RKIP-overexpressing MDCK cells to a less elongated and more cell-cell adhesive state ( Figure 5D ); however, this is not a complete reversion of cells back to a normal cuboidal epithelial phenotype, perhaps because of the relatively short time of exposure to locostatin, the high level of RKIP expression under the control of the human cytomegalovirus (CMV) promoter, or the simultaneous inhibition of the compound's other targets. It would have been interesting to grow the RKIP-overexpressing cells in the presence of locostatin; however, this was not possible since locostatin also inhibits cell proliferation [1] . However, the ability of locostatin to inhibit cell migration and wound closure is dramatically reduced when RKIP is overexpressed ( Figure 6 ). There is little effect on the migration of RKIP-overexpressing cells with treatment of locostatin at subtoxic concentrations that strongly inhibit wound closure in control MDCK cells. At higher concentrations, locostatin is similarly toxic in both the RKIP-overexpressing MDCK cells and control cells. This suggests that the toxicity of the compound at higher concentrations is mediated by the inhibition of other targets, while the subtoxic antimigratory effect is due to the inhibition of RKIP. In addition, the RKIP-overexpressing cells tend to round up and die with long-term maintenance of the cultures at confluence, consistent with previous work showing that RKIP has proapoptotic activity in human prostate and breast cancer cells [25] . We found Locostatin also inhibits POP with a second-order inactivation rate constant of 2.08 M −1 s −1 (Table S2) 70 (m, 1H, CHN), 4.22-4.16 (m, 2H, CH 2 O), 3.33 (dd, 1H, J = 3 153.36, 146.93, 135.28, 129.37, 128.85, 127.22, 121.75, 66.01, 55.20 
Locostatin Reveals the Role of RKIP in Cell Migration
Expression and Purification of Recombinant Genes
We expressed recombinant genes in Escherichia coli (DH5α or JM109 strains) following CaCl 2 -mediated transformation of the bacteria. Rat RKIP fused to GST in the pGEX-KG vector was expressed and purified as previously described [6] . His 6 -tagged GSTO1-1 in pQE30 was expressed and purified as previously described [40] . His 6 -tagged POP in pCHH29 was also expressed and purified as previously described [41] . The Raf-1 kinase assay involved multiple recombinant kinases: Raf-1, a kinase-negative mutant of extracellular signal-regulated kinase 2 (ERK2) and mitogenactivated protein kinase/ERK kinase 1 (MEK1). GST-Raf-1 in pEBG, GST-MEK1 in pGEX-KG, and GST-ERK2 in pGEX-KG were expressed and purified as previously described [42] . The GST-Raf-1-containing construct was transfected into COS-7 cells by using lipofectamine and was activated by treating the cells with 100 nM phorbol 12-myristate 13-acetate for 15 min before cell lysis. GSTRaf-1 was purified by using glutathione-agarose beads and was eluted from the beads with 10 mM reduced glutathione. GST was cleaved from all of the recombinant proteins with thrombin. , ammonium sulfate precipitation (50%-60% fraction), gel filtration (the ALDH1A1 tetramer is w220 kDa), and phenyl hydrophobic column chromatography. For purification from A549 cells, the scheme involved Q-sepharose column chromatography (pH 8.0, elution at 200-400 mM NaCl), ammonium sulfate precipitation (50%-60% fraction), gel filtration, and phenyl hydrophobic column chromatography. For purification from bovine liver, the sequence entailed ammonium sulfate precipitation (50%-70% fraction), Q-sepharose column chromatography (pH 8.0, elution w200 mM NaCl), hydrophobic column chromatography, and gel filtration. All steps were done at 4°C.
Purification of ALDH1A1
Raf Kinase Enzyme Assay
The assay involves in vitro reconstitution of the Raf/MEK/ERK cascade as previously described [42] . A total of 3.8 g purified recombinant RKIP, corresponding to 9 M in the initial sample volume, was preincubated at 16°C for 3 hr with 100 M locostatin, or an equivalent volume percent of dimethyl sulfoxide (DMSO) carrier solvent alone, in 20 
GSTO1-1 Enzyme Assay
The DHA reductase and thiol transferase activities of GSTO1-1 were assayed. DHA reductase activity was assayed in 100 mM TrisHCl (pH 8.0), 1 mM reduced glutathione, 0.25 mM DHA, to which GSTO1-1 was added to a final concentration of 1 M. Starting 10 s after the addition of GSTO1-1, absorbance at 265 nm was measured at 5 s intervals for 10 min at 25°C. The thiol transferase activity was assayed in 100 mM Tris-HCl (pH 8.0), 0.5 mM reduced glutathione, 1 mM 2-hydroxyethyl disulfide, 0.4 mM NADPH, 1 U glutathione reductase. Beginning 10 s after the addition of GSTO1-1 to 1 M, absorbance at 340 nm, which decreases with oxidation of NADPH, was measured at 30 s intervals for 10 min at 25°C.
Kinetics of Association of Locostatin with Proteins
The pseudo-first-order rate constant, k obs , was determined by plotting the natural logarithm of the residual enzyme activity or the fractional saturation as a function of time, then calculating the slope of the line, which corresponds to −k obs . The second-order rate constant (known as k assoc or k inact ) for the inhibition of each protein by locostatin was calculated by using the relationship Five different siRNAs were constructed as short hairpin RNAs (shRNAs, also known as hairpin siRNAs) corresponding to different target sequences in the canine RKIP gene, and each was inserted between the new BamHI and SpeI sites, just upstream of the new poly-A signal sequence. Expressed shRNAs are processed in the cell to siRNAs that silence or knock down expression of their targets (for review, see [46] ). The structures of our cloned constructs were confirmed by DNA sequencing. Each construct was then transfected into Tet-Off MDCK cells (BD Biosciences Clontech) by using lipofectamine, according to the manufacturer's protocol (Invitrogen). Stable transfectants were selected and maintained in 400 g/ml hygromycin B and 1 g/ml doxycycline in MEM with 10% NCS, and EGFP-expressing cells were collected. Induction of each shRNA/siRNA was accomplished by withdrawing doxycycline from the medium. Knockdown was confirmed by Western blot analysis by using the same anti-RKIP antibody as described above and then mouse anti-β-actin antibody (Santa Cruz Biotechnology) as loading control. An shRNA/siRNA corresponding to nucleotides 285-303 of the canine RKIP gene was particularly effective at silencing RKIP expression and was therefore used for wound closure experiments. The control was an inert shRNA/siRNA in the same vector that did not affect expression of RKIP. After 4 days in the absence of doxycycline, cell monolayers were scratch wounded and then analyzed, as described earlier. While we found RKIP knockdown even in the presence of doxycycline, indicating "leakiness" of the modified TetOff system, this was not a problem since the cells displayed no obvious changes in growth rate or morphology despite silencing of RKIP expression.
For overexpression of RKIP, the canine RKIP gene was fused to enhanced green fluorescent protein (EGFP) by ligation into the XhoI and XbaI restriction sites of the pEGFP-C1 mammalian expression vector, which drives insert fusion gene expression from the CMV immediate early promoter. After propagation in E. coli, the EGFP-RKIP construct was purified and sequenced to confirm its proper identity. The construct was then transfected into MDCK cells by using lipofectamine, as described above. Stable transfectants were selected and maintained in 500 g/ml G418 sulfate in MEM with 10% NCS. Stable transfectants with empty pEGFP-C1 vector were also prepared as control cells.
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